Drug-induced liver disease

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 1-11

  Kaplowitz, Neil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016048709     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Zimmerman H. Drug Hepatotoxicity. 2nd ed. Philadelphia, PA: Lippincott, 1999.
2. Ostapowicz G, Fontana RB, Larson AM, et al. Etiology and outcome of acute liver failure in the USA:preliminary results of a prospective multi-center study (abstr). Hepatology 1999; 30(4):221A.
3. Shakil A, Kramer D, Mazariegos G, et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transplant 2000; 16:163-9.
4. Larsen A, Polson J, Fontana R, et al. Acetaminophen-induced acute liver failure: results of a U.S. Multicenter, prospective study. Hepatology 2005; 42:1364-72.
5. Zimmerman H. Drug-induced liver disease. In: Schiff E, Sorrell M, Maddrey W, eds. Schiff’s Diseases of the Liver. 8th ed. Philadelphia, PA: Lippincott-Raven, 1999:973-1064.
6. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French populationbased study. Hepatology 2002; 36:451-5.
7. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61:135-43.
8. Kaplowitz N. Drug metabolism and hepatotoxicity. In: Kaplowitz N, ed. Liver and Biliary Diseases. 2nd ed. Baltimore, MD: Williams & Wilkins, 1996:103-20.
9. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42:481-9.
10. Andrade R, Lucena M, Fernandez M, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512-21.
11. Lewis JH. “Hy’s law”, the “Rezulin rule” and other predictors of severe drug-induced hepatotoxicity:putting risk-benefit perspective. Pharmacoepidemiol Drug Saf 2006; 15:221-9.
12. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997; 26:31-5.
13. Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15:244-51.
14. Van Steenberen W, Peeters P, DeBondt J, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol 1998; 29:135-41.
15. Pham T-V, Lu S, Kaplowitz N. Acetaminophen hepatotoxicity. In: Taylor MB, ed. Gastrointestinal Emergencies. 2nd ed Baltimore, MD: Williams & Wilkins, 1997:371-88.
16. Tarazi E, Harter JG, Zimmerman HJ, et al. Sulindac-associated hepatic injury. Analysis of 91 cases reported to the food and drug administration. Gastroenterology 1993; 104:569-74.
17. Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82:1826-32.
18. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination. Report of 15 cases. Gut 1992; 33:368-71.
19. Thompson N, Caplin M, Hamilton M, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8:1384-8.
20. Murphy E, Davern T, Shakil O, et al. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci 2000; 45:549-53.
21. Rieder M, Uetrecht J, Shear N, et al. Diagnosis of sulfonamide hypersensitivity reactions by in vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med 1999; 110:286-9.
22. Rieder M, Shear N, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49:13-7.
23. Gennis M, Vemusi R, Burns E, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91:631-4.
24. Becquemont L, Lecoeur S, Simon T, et al. Glutathione S-transferase θ genetic polymorphism might influence tacrine in Alzheimer’s patients. Pharmacogenetics 1997; 7:251-3.
25. Robin M, LeRoy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26(1):23-30.
26. Berson A, DeBeco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114:764-74.
27. Brinkman K, Hofstede H, Burger D, et al. Adverse effects of reverse transcriptase inhibitors:mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-44.
28. Kowdley K, Keefe E. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am 1995; 24:991-1001.
29. Czaja M, Xu J, Alt E. Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology 1995; 108:1849-54.
30. Hogaboam C, Bone-Larson C, Steinhauser M, et al. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. Am J Pathol 2000; 156:1245-52.
31. Laskin D, Gardner C, Price V, Jollow D. Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology 1995; 21:1045-50.
32. Bourdi M, Masubuchi Y, Reilly TP, et al. Protection against acetaminophen induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002; 35:289-98.
33. Liu Z-X, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004; 127:1760-74.
34. Cressman P, Greenbaum L, DeAngelis R, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274:1379-83.
35. DeLeve L, Kaplowitz N. Prevention and therapy of drug-induced hepatic injury. In: Wolfe M, ed. Therapy of Digestive Disorders Philadelphia, PA: WB Saunders/Harcourt Brace & Company, 2000:334-48.
36. Nuwayser E, Bittner M, Trent J, et al. Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog 1999; 24:153-9.
37. Beaune P, Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs. J Hepatol 1997; 26(Suppl. 2):37-42.
38. Neuberger J. Immune mechanisms in drag hepatotoxicity. Clin Liver Dis 1998; 2:471-82.
39. Maria V, Victorino R. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664-9.
40. Benichou C. Criteria of drug induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11:272-6.
41. Danan G, Benichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-30.
42. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs II. An original model or validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46:1331-6.
43. Lucena M, Camargo R, Andrade R, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33:123-30.
44. Kaplowitz N. Causality assessment versus guilt by association in drug hepatotoxicity. Hepatology 2001; 33:308-10.
45. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4:489-99.
46. Watkins P, Whitcomb R. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916-7.
47. Moses P, Schroeder B, Alkhatib O, et al. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999; 94:1393-6.
48. Walker A, Cavanaugh R. The occurrence of new hepatic disorders in a defined population. Post Mark Surveill 1992; 6:107-17.
49. Carson J, Strom B, Duff A, et al. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med 1993; 153:1331-6.
50. Dun M-S, Walker A, Kronlund K. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf 1999; 8:275-83.